Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.51 |
| ▸ | MDM4 | O15151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10417439 | 1.00 | TLR2 (0.55) | TLR2MDM2MDM4TP53PTPN1 | |
| SCHEMBL10418082 | 0.91 | MDM2 (0.49) | TLR2MDM2MDM4TP53PTPN1 | |
| SCHEMBL30863677 | 0.91 | MDM2 (0.49) | TLR2MDM2MDM4TP53PTPN1 | |
| SCHEMBL24709082 | 0.85 | MDM2 (0.53) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL26195497 | 0.85 | MDM2 (0.53) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL10417447 | 0.83 | PTPN1 (0.54) | PTPN1 | |
| SCHEMBL31370449 | 0.83 | TLR2 (0.60) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL119437 | 0.83 | TLR2 (0.60) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL12917713 | 0.83 | TLR2 (0.67) | TLR2MDM2MDM4TP53CASP3 | |
| SCHEMBL120504 | 0.81 | TLR2 (0.55) | TLR2MDM2MDM4TP53PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612428-B2 | Process for solid-phase peptide synthesis and device | KREUZER OLIVER JOHANNES (DE) | 2026-04-28 | — | — | US | disclosed |
| CN-113646322-B | Solid phase peptide synthesis method and device | 奥利弗·约翰内斯·克鲁泽 | 2024-07-05 | — | — | CN | disclosed |
| EP-3911661-B1 | ULTRASOUND ASSISTED PROCESS FOR SOLID-PHASE PEPTIDE SYNTHESIS AND DEVICE | KREUZER OLIVER JOHANNES (DE) | 2024-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612428-B2 | Process for solid-phase peptide synthesis and device | MAX, SPATS2L, QPCTL | TLR2 2102/4885MDM2 953/4885MDM4 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.